Baycol LogoChemical structure of cerivastatin
Find information on thousands of medical conditions and prescription drugs.

Cerivastatin

In pharmacology, cerivastatin (Baycol®, Lipobay®) is a synthetic member of the class of statins, used to lower cholesterol and prevent cardiovascular disease. It was withdrawn from the market in 2001 because of the high rate of serious side-effects. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Cerivastatin was marketed by the pharmaceutical company Bayer A.G. in the late 1990s as a new synthetic statin, to compete with Pfizer's highly successful Lipitor®.

During post-marketing surveillance, 52 deaths were reported in patients using cerivastatin, mainly from rhabdomyolysis and its resultant renal failure. Risks were higher in patients using fibrates (mainly gemfibrozil/Lopid®) and in patients using the high (0.8 mg/day) dose of cerivastatin. Another 385 nonfatal cases of rhabdomyolysis were reported. This put the risk of this (rare) complication at 5-10 times that of the other statins.

In 2001, Bayer announced the voluntary withdrawal of the drug from the market.

Important Note

On August 8, 2001 the U.S. Food and Drug Administration FDA announced that Bayer Pharmaceutical Division is voluntarily withdrawing Baycol (cerivastatin) from the U.S. market because of reports of sometimes fatal rhabdomyolysis, a severe muscle adverse reaction from this cholesterol-lowering (lipid-lowering) product . The FDA agrees with and supports this decision. All patients taking Baycol should contact their healthcare providers to discuss treatment alternatives.

Read more at Wikipedia.org


[List your site here Free!]


AD patients may benefit from use of cholesterol-lowering drugs
From Geriatrics, 5/1/04

Source: Zamrini E, McGwin G, Roseman JM. The association between statin use and Alzheimer's disease. Neuroepidemiology 2004; 23(1-2):94-8.

Statin use for up to 12 months has been shown to reduce the risk of Alzheimer's disease (AD) by 39% in patients age >50 who have cardiovascular disease or risk factors, according to a study by researchers at the University of Alabama.

In the nested case-control study, investigators evaluated patients from the Veterans Affairs Medical Center in Birmingham, Alabama, to determine whether statin drugs (eg, atorvastatin, cerivastatin) normally used for patients with hyperlipemic disorders, have any effect on patients with AD; adjustments were made for comorbid medical conditions.

To date, current treatment for AD patients relied on cholinesterase inhibitors, vitamin E, and symptomatic treatment.

Researchers examined 308 new cases of AD, diagnosed between 1997 and 2001, along with age-matched non-AD controls (n=3,088). Because females represented what study authors deemed a small proportion of the patient population (10.8%), they were excluded from the study.

The raw proportion of patients who filled their statin prescription prior to their AD diagnosis was 12.6% among cases; 15.1% among controls (OR 0.81, 95% CI 0.57-1.15). Compared to non-users, those with less than one year of statin use experienced reduced risk of AD (OR 0.56, 95% CI 0.34-0.92). Reductions were present among patients with hypertension, ischemic heart disease and cerebrovascular disease. Conversely, for patients with no cardiovascular risk factors, no association between statin use and lowered risk of AD was found.

Researchers identified 5 potential hypotheses for how statins may work to reduce dementia risk:

* Statins are designed to reduce an elevated cholesterol level, which is linked to an increased AD risk;

* Statins have a positive effect on cardiovascular risk, which is also a risk factor for AD;

* Statins affect production of [beta]-amyloid;

* Statins affect vascular dilation through nitric oxide;

* Statins affect inflammatory and oxidative stress markers tied to hyperlipidemia.

The authors acknowledge that the current study does not favor any one of their five hypotheses and recommend that more AD-statin association trials be conducted. Additionally, the authors recommend a closer examination of medication dosage, target cholesterol levels, and the role of different statins in future trials.

One limit of the study is that it cannot be generalized to cover AD patients who do not have the CVDs assessed in the study. Secondly, authors did not find a notable effect of duration of statin use and reduced risk of AD, suggesting that statin use pertaining to AD may have short-term effect only. Third, the study was limited to males only.

In conclusion, this study's results contribute to mounting evidence of an inverse association between AD diagnosis and statin use.

COPYRIGHT 2004 Advanstar Communications, Inc.
COPYRIGHT 2004 Gale Group

Return to Cerivastatin
Home Contact Resources Exchange Links ebay